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Cobalt(II) chloride reacts with 2-aminobenzimidazole derivatives to give complexes 
of the formula [CoL2Cl2], where L=2-aminobenzimidazole, 1-benzyl-2-aminobenzimida-
zole and 1-(4-methylbenzyl)-2-aminobenzimidazole. All the ligands and their cobalt(II) 
complexes were evaluated for their in vitro antimicrobial activity against Pseudomonas 
aeruginosa, Bacillus sp., Staphylococcus aureus, Sarcina lutea and Saccharomyces ce-
revisiae. The minimum inhibitory concentration (MIC) was determined for all ligands and 
their complexes. It was found that tested compounds were more active against gram-po-
sitive than gram-negative bacteria. None of the compounds were significantly effective 
against yeast Saccharomyces cerevisiae, except 2-aminobenzimidazole complex, which 
moderately inhibited the growth of yeast. 1-(4-methylbenzil)-2-aminobenzimidazole was 
found to be slightly active against Saccharomyces cerevisiae. The same ligand showed 
the lowest MIC value of 60 µg/ml against Pseudomonas aeruginosa, as well as 125 µg/ml, 
against Bacillus sp. and Sarcina lutea. The MIC value of its cobalt(II) complex was 60 
µg/ml against Pseudomonas aeruginosa. Cobalt(II) complex with 1-benzyl-2-aminobenz-
imidazole showed the lowest MIC value of 60 µg/ml against Staphylococcus aureus. The 
effect of ligand and complex structure on the antimicrobial activity was discussed. 
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INTRODUCTION 
Benzimidazole and its derivatives are interesting heterocycles because of their 
presence in many various medicaments. It has been found that they possess antibacterial, 
antifungal, antihistaminic, cytostatic, local analgesic, hypotensive and antiinflammatory 
activity (1-6). It was confirmed to have a moderate in vitro anti-HIV activity (7,8). In recent 
years, transition metal complexes have attracted particular interest because of their poten- 
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potential use in several homogeneously catalyzed processes, such as hydrogenation, hyd-
roformylation and acetylation reactions. However, in the recent time, possible therape-
utic properties of the metal complexes have been examined. It was found that the complexes 
of transition metals with benzimidazole derivatives showed a higher antimicrobial acti-
vitiy than the corresponding ligands (9-13).  
Following our studies of the reactivity of benzimidazole derivatives with metallic 
halides (10-13), we evaluated the antimicrobial activity of this type of complexes in this 
study. We report in vitro antimicrobial activities of 2-amino benzimidazoles and their co-
balt(II) complexes against three gram-positive bacterial strains: Bacillus sp., Staphylococcus 
aureus and Sarcina lutea, one gram-negative isolate: Pseudomonas aeruginosa and yeast, 
Saccharomyces cerevisiae.  
EXPERIMENTAL 
Reagents 
All chemicals used to prepare the ligands and complexes were of analytical reagent 
grade, commercially available from different sources. The ligands were synthesized as de-
scribed in the literature (14). 
Synthesis of complexes 
All the complexes were prepared following the same procedure. A solution of 5 mmol of 
CoCl2 × 6H2O in 10 cm
3 of EtOH was added to a solution of 10 mmol of the ligands (2-
aminobenzimidazole (L
1), 1-benzyl-2-aminobenzimidazole (L
2) and 1-(4-methylbenzil)-2-
aminobenzimidazole (L
3)) in 10 cm
3 EtOH. The resulting mixture was boiled under reflux 
on a water bath for about 2 h and then cooled. The complexes were separated from the re-
action mixture by filtration, washed with EtOH and dried in vacuo over CaCl2. 
Antimicrobial investigations 
Antimicrobial activity was tested by the disc-diffusion method under standard con-
ditions, using Mueller-Hinton agar medium as described by NCCLS (15). Each of the 
investigated isolates of bacteria was seeded in the tubes with nutrient broth (NB), and 1 
cm
3 of seeded NB and homogenized was taken in tubes with 9 cm
3 of melted (45°C) 
nutrient agar (NA). The homogeneous suspension was poured out in Petri dishes. The 
discs of filter paper (diameter 5 mm) were ranged on cool medium. After cooling on formed 
solid medium, 2⋅10
-5dm
3 of the investigated compounds (γ=1000 µg/ml) were placed by 
micropipette. After incubation for 24 hours in thermostat at 25-27°C, inhibition (sterile) 
zone diameters (including disc) were measured and expressed in mm. Inhibition zone 
diameter over 8 mm indicates the tested compound is active against microorganisms 
under investigation. Every test was done in three replications. In parallel with antimicro-
bial investigations of the complexes, ligands were tested too. 
Minimum inhibitory concentration was determined by the agar dilution method 
according to guidelines established by the NCCLS standard M7-A5 (16). MIC was descri-233 
bed as the lowest concentration of the compound that visibly inhibited colony`s growth. 
Stock solutions of the compounds were prepared in dimethylformamide (DMF). Further 
dilutions were performed with distilled water. The concentration range of the compounds 
tested was between 60-750 µg/ml in two-fold dilution steps. The inoculated plates were then 
incubated at 35°C for 16-20 h. 
RESULTS AND DISCUSSION 
The antimicrobial activity of the 2-aminobenzimidazole derivatives and their cobalt 
(II) complexes was tested first by the agar disc-diffusion method against gram-positive and 
gram-negative bacteria and yeast. The results of these studies are summarized in Table 1. 
From the data given in Table 1 it is clear that the tested compounds were more active 
against gram-positive bacteria than against gram-negative Pseudomonas aeruginosa. It 
may be concluded that the antimicrobial activity of the compounds is related to cell wall 
structure of the bacteria. 
Table 1. In vitro antimicrobial activity of ligands and their complexes 
at a concentration of 1000 µg/ml 
Compound  P. aeruginosa  Bacillus sp.  S. aureus  S. lutea  S. cerevisiae 
L
1 +  ∅  ∅  ∅  ∅ 
[Co(L
1)2Cl2]  ∅  +++ +++  +++ ++ 
L
2 +  ++  ++  ++  ∅ 
[Co(L
2)2Cl2] +++ +++  +++  +++  ∅ 
L
3 ++  ++++  ++++  ++++  + 
[Co(L
3)2Cl2] +++ +++  +++  +++  ∅ 
Very highly active ++++, Highly active +++, Moderately active ++, Slightly active +, Inactive ∅ 
None of the compounds were found to be significantly effective against yeast Saccha-
romyces cerevisiae, except for [Co(L
1)2Cl2], which moderately inhibited the growth of 
yeast. 1-(4-methylbenzil)-2-aminobenzimidazole (L
3) was found to be slightly active against 
Saccharomyces cerevisiae. 
Table 2. Antimicrobial activities of ligands and their complexes against Pseudomonas aeruginosa 
at different concentrations  
Concentration (µg/ml) 
Compound 
750 500  250  125  60 
L
2 +  ∅  ∅  ∅  ∅ 
[Co(L
2)2Cl2] ++  +  +  ∅  ∅ 
L
3 +++  ++  ++  ++  + 
[Co(L
2)2Cl2] +++  ++  ++  ++  + 234 
Table 3. Antimicrobial activities of ligands and their complexes against Bacillus sp. 
at different concentrations 
Concentration (µg/ml) 
Compound 
750 500  250  125  60 
[Co(L
1)2Cl2] ++  +  +  ∅  ∅ 
L
2 +  +  ∅  ∅  ∅ 
[Co(L
2)2Cl2] ++  +  +  ∅  ∅ 
L
3 ++  ++  +  + ∅ 
[Co(L
2)2Cl2] ++  ++  +  ∅  ∅ 
Table 4. Antimicrobial activities of ligands and their complexes against Staphylococcus aureus 
at different concentrations 
Concentration (µg/ml) 
Compound 
750 500  250  125  60 
[Co(L
1)2Cl2] ++  ++  +  ∅  ∅ 
L
2 +  ∅  ∅  ∅  ∅ 
[Co(L
2)2Cl2] ++  ++  ++  ++  + 
L
3 +++  ++ ++  +  ∅ 
[Co(L
2)2Cl2] ++  ++  ++  ∅  ∅ 
Table 5. Antimicrobial activities of ligands and their complexes against Sarcina lutea 
at different concentrations 
Concentration (µg/ml) 
Compound 
750 500  250  125  60 
[Co(L
1)2Cl2] ++  +  +  ∅  ∅ 
L
2 +  +  ∅  ∅  ∅ 
[Co(L
2)2Cl2] ++  +  +  ∅  ∅ 
L
3 ++  ++  + +  ∅ 
[Co(L
2)2Cl2] ++  ++  +  ∅  ∅ 
The results of MIC determination by the agar dilution method are presented in Tables 
2-5. The compounds not shown in the table had no antibacterial activity at the tested con-
centration.  
The results presented in Tables 2-5 indicate that the complex containing cobalt(II) 
was more active than the starting ligand L
1 against Bacillus sp., Staphylococcus aureus 
and Sarcina lutea with a MIC value of 250 µg/ml, but less active against Pseudomonas 
aeruginosa. On the other hand, the cobaltl(II) complex was more active than the starting 
ligand L
2, with a MIC value of 250 µg/ml, and equally active as ligand L
3 with a MIC va-
lue of 60 µg/ml against Pseudomonas aeruginosa. In the cases of other bacteria the com-
plex was more active than its ligand L
2, but less active than ligand L
3. MIC value of 235 
[Co(L
2)2Cl2] was 250 µg/ml, against Bacillus sp. and Sarcina lutea, as wel as 60µg/ml 
against Staphylococcus aureus. The complex containing L
3 were active against Bacillus 
sp., Sarcina lutea and Staphylococcus aureus with a MIC value of 250µg/ml, but its li-
gand was more toxic, with a MIC value of 125 µg/ml, against the same bacteria. Com-
paring the activities of the tested ligands and their complexes, it was found that if the 
benzimidazole nucleus was substituted with a 4-methylbenzyl group at the N1 atom, the 
antimicrobial activity increased (14). Considering of the structural formula of the com-
pounds that exhibited antimicrobial activity, it can be concluded that substituted ligands 
and cobalt moiety may play a role in the antimicrobial activity. The antimicrobial potenti-
als of the investigated benzimidazole derivatives are similar to those of different benz-
imidazoles that were determined in the previous studies (2-4, 10-14). 
CONCLUSIONS 
Cobalt(II) chloride reacts with 2-aminobenzimidazole derivatives to give complexes 
of the formula [CoL2Cl2], where L
1=2-aminobenzimidazole, L
2=1-benzyl-2-aminobenz-
imidazole and L
3=1-(4-methylbenzyl)-2-aminobenzimidazole. All the ligands and their co-
balt(II) complexes were evaluated for their in vitro antimicrobial activity against Pseudo-
monas aeruginosa, Bacillus sp., Staphylococcus aureus, Sarcina lutea and Saccharo-
myces cerevisiae. It was found that the tested compounds were more active against gram-
positive than gram-negative bacteria. None of the compounds were significantly effective 
against yeast Saccharomyces cerevisiae, except for the 2-aminobenzimidazole complex, 
which moderately inhibited the growth of yeast. 1-(4-methylbenzil)-2-aminobenzimida-
zole was found to be slightly active against Saccharomyces cerevisiae. The complex was 
more active than the starting ligand L
1 against Bacillus sp., Staphylococcus aureus and 
Sarcina lutea with a MIC value of 250 µg/ml. In the case of Pseudomonas aeruginosa 
the complex was less active than its ligand L
1, more active than ligand L
2,with a MIC va-
lue of 250 µg/ml and equally active as ligand L
3, with a MIC value of 60 µg/ml. MIC value 
of L
2 complex was 250µg/ml, against Bacillus sp. and Sarcina lutea, and 60 µg/ml against 
Staphylococcus aureus. The complex containing L
3 was active against Bacillus sp., Sar-
cina lutea and Staphylococcus aureus, with a MIC value of 250 µg/ml, but its ligand was 
more toxic, with a MIC value of 125 µg/ml against the same bacteria. Comparing the ac-
tivities of the tested ligands and their complexes, it was found that if the benzimidazole 
nucleus was substituted with a 4-methylbenzyl group at the N1 atom, the antimicrobial 
activity increased. On considering the structural formula of the compounds that exhibited 
antimicrobial activity, it can be concluded that substituted ligands and cobalt moiety may 
play a role in the antimicrobial activity.  
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АНТИМИКРОБНА АКТИВНОСТ КОБАЛТ(II) КОМПЛЕКСА СА 
ДЕРИВАТИМА 2-АМИНОБЕНЗИМИДАЗОЛА 
Сања О. Подунавац-Кузмановић, Драгољуб М. Цветковић и Гордана С. Ћетковић 
Кобалт(II)-хлорид реагује са дериватима 2-аминобензимидазола дајући комп-
лексе типа [CoL2Cl2] (L=2-аминобензимидазол, 1-бензил-2-аминобензимидазол и 1-
(4-метилбензил)-2-аминобензимидазол). Испитана је антимикробна активност лига-
нада и њихових комплекса са кобалтом на Pseudomonas aeruginosa, Bacillus sp., 
Staphylococcus aureus, Sarcina lutea и Saccharomyces cerevisiae. За све лиганде и 
њихове комплексе oдређена је минимална инхибиторна концентрација (МИК). Ис-
питивана једињења показују већу инхибиторну активност према грам-позитивним, 
него према грам-негативним бактеријама. Ниједно од испитиваних једињења, изу-
зев 2-аминобензимидазола, не показује значајнију активност на раст квасца Saccha-
romyces cerevisiae. 1-(4-метилбензил)-2-аминобензимидазол показује веома слаб ин-
хибиторни ефекат на квасац. За Pseudomonas aeruginosa најнижу МИК вредност има-
ју 1-(4-метилбензил)-2-аминобензимидазол и његов комплекс и она износи 60 µg/ml. 
МИК за Bacillus sp.и Sarcina lutea је такође најнижа за 1-(4-метилбензил)-2-амино-
бензимидазол и износи 125 µg/ml. За бактерију Staphylococcus aureus најнижа МИК 
је 60 µg/ml и карактеристична је за комплекс кобалта(II) са 1-бензил-2-аминобензими-
дазолом. Дискутован је утицај структуре лиганда и комплекса на њихову антимик-
робну активност. 
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